CeraPedics Closes $12.25M PE Financing

CeraPedics (Lakewood, CO) developing products for the orthopedic bone substitute market announced the close of a $12.25M private equity financing from OrbiMed Advisors. The Company’s products utilize a proprietary small peptide called P-15™. This peptide has been identified to play a role in initiating the formation of bone. CeraPedics’ products may provide a safe, efficacious, and economical alternative to autograft and recombinant bone growth factor products for most procedures requiring a bone graft including spine fusion, trauma, and joint reconstruction. CeraPedics’ first product, P-15 Putty, is currently under an Investigational Device Exemption (IDE) clinical investigation for FDA regulatory approval.

Glucon, Inc.: Series D Undisclosed

Glucon (Boulder) developer of a blood glucose measurement system raised an undisclosed amount of Series D funding. The deal was led by the 3i Group and was joined by Sequel Venture Partners, Quest Capital Partnership, Hunt Ventures and previous investors Aurum Ventures, Giza Venture Capital, MKI, Infinity Venture Capital Fund and Ascend Technology Ventures.

iBalance Rounds Out $13.5M Series A

iBalance Medical (Boulder) is developing an improved method for completing an orthopedic surgical procedure called high tibial osteotomy. The company provides the surgical tools and implant for this knee malalignment corrective surgery. Back in October of 2005 I wrote about the $8.24M first tranche (here). The company has recently announced a second $5.26M tranche (also mentioned on my other blog OnBioVC here, yet another shameless self plug) bringing the total raised to $13.5M. Well done!